ARRIVENT BIOPHARMA
ArriVent is a biopharmaceutical company developing pharmaceutical products to cure presently untreatable cancer.
ARRIVENT BIOPHARMA
Social Links:
Industry:
Biotechnology Life Science Pharmaceutical
Founded:
2021-01-01
Address:
Pennsylvania Furnace, Pennsylvania, United States
Country:
United States
Website Url:
http://www.arrivent.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
305 M USD
Technology used in webpage:
Person Schema Gravatar Profiles U.S. Server Location Akamai Hosted
Similar Organizations
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
EpiVario
EpiVario develops novel compounds to treat memory-related psychiatric disorders at the source of the disease.
Iroko Pharmaceuticals
Iroko Pharmaceuticals is a global specialty pharmaceutical company dedicated to advancing the science of analgesia.
Current Employees Featured
Founder
Stock Details
Investors List
Infinitum Partners
Infinitum Partners investment in Series B - ArriVent Biopharma
Sirona Capital
Sirona Capital investment in Series B - ArriVent Biopharma
HBM Partners
HBM Partners investment in Series B - ArriVent Biopharma
Shanghai Healthcare Capital
Shanghai Healthcare Capital investment in Series B - ArriVent Biopharma
Lilly Asia Ventures
Lilly Asia Ventures investment in Series B - ArriVent Biopharma
Catalio Capital Management
Catalio Capital Management investment in Series B - ArriVent Biopharma
AIHC Capital
AIHC Capital investment in Series B - ArriVent Biopharma
Boyu Capital
Boyu Capital investment in Series B - ArriVent Biopharma
Sequoia Capital China
Sequoia Capital China investment in Series B - ArriVent Biopharma
HBM Healthcare Investments
HBM Healthcare Investments investment in Series B - ArriVent Biopharma
Key Employee Changes
| Date | New article |
|---|---|
| 2024-01-05 | ArriVent Appoints Winston Kung as Chief Financial Officer and Treasurer |
Official Site Inspections
http://www.arrivent.com Semrush global rank: 3.58 M Semrush visits lastest month: 3.62 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "ArriVent Biopharma"
About - ArriVent Biopharma
Arrivent was founded in 2021 with a mission to identify, develop and commercialize differentiated medicines from around the world to address the unmet medical needs of patients with difficult …See details»
ArriVent Biopharma - Crunchbase Company Profile & Funding
ArriVent Biopharma closed its last funding round on Dec 29, 2022 from a Series B round. Who are ArriVent Biopharma 's competitors? Alternatives and possible competitors to ArriVent …See details»
Investor Relations - ArriVent Biopharma
Sep 9, 2024 With a deep and global network, ArriVent seeks to access unique and best-in-class drug candidates at various development stages, including those coming from China and other …See details»
ArriVent BioPharma Reports Full Year 2024 Financial
Mar 3, 2025 ArriVent anticipates having top-line data in 2025 and expects to provide an update on timing of the top-line Phase 3 data release in Q2 2025. 2024 Financial ResultsSee details»
About Arrivent Biopharma Inc (AVBP) - Investing.com
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical …See details»
SEC Filing - ArriVent Biopharma
(State of Other Jurisdiction of incorporation or Organization) ... (Bing) Yao, Ph.D. Prior to ArriVent, Dr. Yao was Chief Executive Officer and Chairman of Viela Bio, Inc. (Viela), which he co …See details»
ArriVent Biopharma - VentureRadar
With a deep and global network, ArriVent seeks to access unique and best-in-class drug candidates at various development stages, including those coming from China and other …See details»
ArriVent BioPharma Reports 2024 Financial Results and Key …
Mar 5, 2025 Overall, ArriVent posted a net loss of $80.5 million for 2024, compared to $69.3 million the previous year. Looking Ahead. Building on a productive 2024, ArriVent aims to …See details»
SEC Filing - ArriVent Biopharma
NEWTOWN SQUARE, PA, November 14, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to …See details»
Press Release Distribution and Management - GlobeNewswire
NEWTOWN SQUARE, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- ArriVent Biopharma, Inc., industry leaders dedicated to accelerating the global development of innovative …See details»
PROGRAMS - ArriVent Biopharma
Firmonertinib is being developed in China by Allist Pharmaceuticals and in the rest of the world by ArriVent BioPharma. ARR-217. We entered into an exclusive license agreement with Lepu …See details»
ArriVent BioPharma appoints PwC as new auditor - Investing.com
Mar 13, 2025 ArriVent BioPharma has provided KPMG with the disclosures regarding the change of auditors and has received a letter from KPMG, dated today, agreeing with the …See details»
ArriVent raises $150M to bring Chinese drugs to Western markets
Jun 30, 2021 Armed with the cash, ArriVent has struck a deal with Allist Pharma for the ex-China rights to furmonertinib, an EGFR TKI that recently won approval in NSCLC in China and …See details»
ArriVent Biopharma - Updates, News, Events, Signals & Triggers
ArriVent develops pharmaceutical products to cure presently untreatable cancer. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. Log In. …See details»
How Does ArriVent Biopharma Work? – CanvasBusinessModel.com
Dec 19, 2024 ArriVent Biopharma is a cutting-edge biotechnology company revolutionizing the field of drug development through its innovative approach. By leveraging advanced …See details»
Then there were two: ArriVent set to list after $175m IPO
Jan 26, 2024 ArriVent BioPharma was beaten to the first biotech initial public offering of the year when CG Oncology made its debut on the Nasdaq yesterday, but is due to start trading on the …See details»
Privacy Policy - ArriVent BioPharma
ArriVent’s EU Representative is The DPO Centre, who can be contacted: By email: [email protected] By telephone: +34919053074 By post at: Calle Méndez Álvaro 20, …See details»
Clinical Trials - ArriVent Biopharma
ArriVent is studying firmonertinib (previously furmonertinib) globally in patients with NSCLC with EGFR mutations or HER2 exon 20 insertion mutations. To learn more about these clinical …See details»
Senior Manager/Associate Director, Clinical Data Management
The Senior Manager/Associate Director of Clinical Data Management will be responsible for leading and managing the data management activities for several clinical trials.See details»